Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Maintenance After ASCT in Relapsed, Refractory or High-risk Lymphoma
NCT03611231Phase 2Unknown
- Sponsor
- Peking University
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in lymphoma, sponsored by Peking University. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT03611231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611231.